Medtronic, Inc. Announces Market Introduction And FDA Approval Of Three New Pacemakers; Physiologic, Fully Automatic Adapta Pacemaker Portfolio Safeguards Cardiac Function And Raises The Standard Of Care For Patients

Medtronic, Inc., (NYSE:MDT) today announced the market introduction of its portfolio of fully automatic pacemakers, the Medtronic Adapta(TM), Versa(TM), and Sensia(TM) pacemakers. These pacing systems provide physiologic pacing adapted to the needs of individual patients, helping set new standards of care that reduce unnecessary pacing when the heart's natural conduction is present. The portfolio recently received approval by the United States Food & Drug Administration.